ArticleChinese herbal medicines2026
Yu-Ping-Feng-San mitigates development of emphysema and its exacerbation induced by influenza virus in mice.
Article in Chinese herbal medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Yu-Ping-Feng-San (YPFS) has been found to significantly reduce exacerbation rate and the risk of a second exacerbation in patients with chronic obstructive pulmonary disease (COPD). However, the effect of YPFS on emphysema development and its exacerbation caused by influenza virus is still unclear. This study aims to investigate the protective effect of YPFS on the impaired lung function and increased inflammation that occurs during the development and exacerbation of emphysema. Methods: This study developed an emphysema mice model using porcine pancreatic elastase (PPE) and treated it with YPFS [1 950, 975, and 487.5 mg/(kg·d)] once daily. On day 7 post-PPE challenge, peripheral leucocytes and inflammatory cells in lungs were analyzed, respectively. Pulmonary inflammatory mediators were determined. On day 28, invasive lung function and inflammatory mediators were measured. In addition, histopathological changes at both time points were assessed. We also developed an exacerbation of emphysema mouse model by intratracheally infected mice with influenza H1N1 virus on day 28. After infection, YPFS administration was discontinued, and the protective effect was determined by lung function, viral titer and cytokine levels in the lungs, and lung histopathological changes on day 5 post-infection. Results: The results demonstrated that 32 days of YPFS administration significantly improved lung function and reduced severity of emphysema in PPE-treated mice. It significantly reduced monocytes and neutrophils, while increased lymphocytes in peripheral blood. Additionally, YPFS inhibited the accumulation of alveolar macrophages and the expression of cytokines in mice treated with PPE. MMP-9, fibronectin, and VEGF, which are inflammatory mediators associated with airway remodeling, were also inhibited by YPFS. The results also demonstrated that YPFS prophylaxis prior to viral infection benefited mice treated with PPE and H1N1 as evidenced by decreased lung cytokine levels, lowered lung index, and improved lung histopathology. Conclusion: YPFS prevents the development of emphysema and its exacerbation induced by influenza virus in mice. Our finding provides scientific evidence for the prophylaxis application of YPFS in mitigating acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.